Overweight and obesity may affect the likelihood of achieving remission in early rheumatoid arthritis (RA), says study published in Arthritis Care & Research. A separate study in Arthritis & Rheumatology focuses on weight change in early RA and patients' subsequent risk of early death. Research has suggested that weight may influence the effectiveness of RA therapies. In an Arthritis Care & Research study, Susan Goodman, MD, of the Hospital for Special Surgery and Weill Cornell Medical School, and her colleagues investigated the potential impact of weight on the likelihood that patients would achieve remission in the early years after an RA diagnosis. The team examined data from the Canadian Early Arthritis Cohort, a multicenter observational trial of patients with early RA who were treated by rheumatologists using guideline-based care.
‘Compared with patients with a healthy BMI, overweight patients were 25% and obese patients were 47% less likely to experience sustained remission despite receiving similar treatments.’"Our study looks at people with recently diagnosed, early RA, who should have the best outcomes and best responses to treatment, and sees how many are either overweight or obese, and then determines if those who are overweight or obese have worse outcomes than those with healthy weight," said Dr. Goodman.
Tweet it Now
Of 982 patients, 32 percent had a healthy BMI, 35 percent were overweight, and 33 percent were obese. Within three years, 36 percent of patients experienced sustained remission. Compared with patients with a healthy BMI, those who were overweight were 25 percent less likely to experience sustained remission, and those who were obese were 47 percent less likely to do so, despite receiving similar treatments.
The research represents the largest study demonstrating the negative impact of excess weight on the RA disease activity and supports a call to action to better identify and address this risk in patients.
"These findings have important implications for clinical care since rates of overweight and obesity continue to rise," said Dr. Goodman. "Our findings highlight the high proportion of newly diagnosed RA patients who are overweight or obese and who may have disease that is harder to treat. For people with RA who haven't had an adequate response to treatment, this may be another factor to consider."
In other studies, obesity has been associated with a decreased risk of early death; however, follow-up studies suggest that this "obesity paradox" may be explained by unintentional weight loss in the few years preceding death, rather than a truly protective effect of obesity. According to this explanation, patients with longstanding RA who reached normal or underweight BMI have higher observed mortality and are relatively less healthy than RA patients who maintained obesity or overweight.
Women with RA had higher mortality rates than women without RA. Among women with RA, 41 percent died during an average follow-up of 17.0 years after the early RA period; among women without RA, 29.2 percent died during an average follow-up of 18.4 years. In both groups, women who had severe weight loss (>30 pounds) had the highest mortality rates after the early RA period. Weight gain in the early RA period was not associated with mortality for either group.